home > news > 2011 > june > simcyp appoints dr iain gardner as head of translational science in dmpk
Simcyp appoints Dr Iain Gardner as Head of Translational Science in DMPK
Date: 21 Jun 2011
Simcyp Limited is delighted to announce that Dr Iain Gardner (BPharm, PhD) is joining its R&D team as Head of Translational Science in DMPK. This appointment further enhances the specialist team within Simcyp and strengthens the company’s ongoing scientific expansion, particularly in the development of PBPK models for biologics.
Dr Gardner brings extensive industry experience, gained most recently from his time in the Pharmacokinetics, Dynamics and Metabolism Group at Pfizer Global Research and Development. As such, Dr Gardner will also be involved in Simcyp’s ongoing collaborative efforts to integrate prior knowledge, share data and propagate pre-competitive information among industry leaders within the Simcyp Consortium.
Commenting on the appointment Dr Gardner said: “I am looking forward to leading the translational DMPK group within Simcyp and am particularly excited to be working with the science team to extend the capabilities of the Simcyp platform to incorporate PBPK models for antibodies and other therapeutic proteins. It’s fantastic to be joining a company that shares my enthusiasm for combining in vitro, in silico and physicochemical information to make assessments of human pharmacokinetics of novel compounds.”
Professor Amin Rostami, Director of Scientific Research and Development at Simcyp, said: “Iain has exceptional wealth and breadth of knowledge on issues related to drug discovery and development, particularly in DMPK. His insight into the challenges facing drug developers, gained over more than a decade in the pharmaceutical industry, will help ensure the practicality of the solutions that Simcyp provides for its Consortium Members and the wider applications of the Simcyp Platform within pre-clinical groups. With the increased number of options we now provide for testing drugs using virtual animals (rat, mouse and dog) we are certain that Iain will have a big impact in leading our science projects related to drug discovery and early drug development”.
Dr Gardner takes up the appointment from 1st July 2011.